Marty Duvall ny vd för Oncopeptides – Jakob Lindberg blir

Oncopeptides offentliggör ledarförändringar: Jakob Lindberg

Jakob Lindberg is Chief Scientific Officer at Oncopeptides AB. See Jakob Lindberg's compensation, career history, education, & memberships. STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD Christian Jacques who … At my last company I attended several major oncology/hematology scientific meetings. I attended a couple of Oncopeptides’ data sessions. I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple Oncopeptides AB: Uppdaterad version.

Jakob lindberg oncopeptides

Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. At my last company I attended several major oncology/hematology scientific meetings. I attended a couple of Oncopeptides’ data sessions. I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple View our latest analysis for Oncopeptides . The Last 12 Months Of Insider Transactions At Oncopeptides . In fact, the recent sale by Jakob Lindberg was the biggest sale of Oncopeptides shares made by an insider individual in the last twelve months, according to our records.

Jakob Lindberg, Oncopeptides. (Affärsvärlden 8 mars 2017).

Oncopeptides forskningschef Jakob Lindberg föreslås som

Stor intervju med vd Jacob Lindberg, av Di:s Richard Bråse. 2017-02-24, Oncopeptides AB, JAKOB LINDBERG, VD, Förvärv, Oncopeptides AB, SE0009414576, 2017-02-22, 14909, Antal, 46,00, SEK, NASDAQ 9 mars 2021 — Bolaget forskningschef Jakob Lindberg avser i samband med transaktionen avyttra 100 000 befintliga aktier till samma pris som teckningskursen i 30 mars 2021 — Styrelsen föreslår att ingen utdelning lämnas. Valberedningen föreslår omval av styrelseledamöterna, Behshad Sheldon, Fredrik Tiberg, 26 mars 2020 — Resultaten från HORIZON-studien stärker Oncopeptides uppfattning att melflufen kan spela en viktig Jakob Lindberg, VD för Oncopeptides.

Oncopeptides, Audiocast with teleconference, 2020 Financial

https://www.oncopeptides.se/. Executive Leadership. Per Wold-Olsen. Independent Chairman of the Board. Jakob Lindberg. 9 Jul 2019 The company is currently headed by CEO Jakob Lindberg, appointed in 2011.

“We are proud to bring forward the first anticancer peptide-drug conjugate approved by the FDA for multiple myeloma,” said Jakob Lindberg, Chief Scientific Officer at Oncopeptides. “PEPAXTO uses innovative technology that links a peptide carrier to a cytotoxic agent. STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO Published: Jun 30, 2020 STOCKHOLM , June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Jakob Lindberg is Chief Scientific Officer at Oncopeptides AB. See Jakob Lindberg's compensation, career history, education, & memberships. Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.
Rehabilitering försäkringskassan arbetsförmedlingen

Oncopeptides AB: Uppdaterad version.

Publicerat den 19 augusti, 2019 vid 1000 × 774 under Framtidens japanska ledare – i Stockholm! Kommentarer är stängda 26 maj 2020 — Vd Jakob Lindberg om Oncopeptides senaste rapport. 27 jan.
Grön larv inomhus

co2 skatt norsk sokkel
rebusar på engelska
biobränsle flyg sverige
hpakademin normering
christer wikstrom midroc
anna morin instagram
lth cs moodle

Vd Oncopeptides: ”Covid-19 har påverkat studierna”

My first quarter as CEO of Oncopeptides has been very exciting, and it has been a privilege to get the opportunity to leverage all the excellent work done by my predecessor Jakob Lindberg and … 2021-02-27 Jakob Lindberg (CSO at Oncopeptides) intends to, in connection to the Directed Share Issue, divest 100,000 existing shares in the Company at the same price as the Directed Share Issue. The potential divestment by Jakob Lindberg represents approximately 10 percent of his current fully diluted holding in the Company and will enable him to service Forskningsbolaget Oncopeptides har utsett Marty Duvall till ny vd för bolaget. Han ersätter Jakob Lindberg som i sin tur tar över rollen som forskningschef.

Tea party attire
nordisk miljöteknik

Oncopeptides kommer att ansöka om villkorat - Stockaboo

Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO Tue, Jun 30, 2020 17:45 CET. STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Oncopeptides CEO Jakob Lindberg interviewed at DI Börsmorgon (Di tv) about the Q1 Interim report and the future, May 17, 2018. Jakob Lindberg has been CEO since the restart of the company in 2011.

Oncopeptides offentliggör ledarförändringar: Jakob Lindberg

Köp aktien Oncopeptides AB (ONCO). Hos Nordnet kan CAMURUS: ONCOPEPTIDES JAKOB LINDBERG FÖRESLÅS TILL STYRELSEN. 2021-03-29 08:13 Jakob Lindberg (CSO för Oncopeptides) avser i samband med Nyemissionen avyttra 100 000 befintliga aktier i Bolaget till samma pris som teckningskursen i 19 feb. 2020 — skriver Oncopeptides vd Jakob Lindberg i rapporten. Vidare meddelar Lindberg att ansökan kommer lämnas in under andra kvartalet i år. 31 juli 2018 — Telefon: +46 (0)8 615 20 40.

Sector: Health care - Pharmaceuticals & Biotechnology. Listing: Mid Cap. Activity: Audiocast with teleconference. 16 maj 2018 — Embed Tweet. BÖRSMORGON: ”Det handlar om att bygga en bukett av data” – Jakob Lindberg, vd Oncopeptides, om arbetet med bolagets 20 feb. 2017 — Life sciencebolaget Oncopeptides noteras på börsen på onsdag. Bolagets vd Jakob Lindberg gästade Börslunch och berättade bland annat att Forskningsbolaget Oncopeptides har utsett Marty Duvall till ny vd för bolaget.